Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1B (migalastat)1件: Migalastat1件: D10359 --1件: 19
2B / Phuket / 3073/2013-like virus)----1件: 53
3B-Lymphocyte Stimulator (BLyS)----1件: 65
4B-peptide-CRM197 conjugate1件: Corynebacterium diphtheriae CRM197 protein---1件: 11
5B. lactis B94----1件: 193
6B. theta----1件: 96
7B001 injection----1件: 13
8B007----1件: 222
9B03BB01----1件: 46
10B2-ASmedic----1件: 97
11B6, B12, L-methylfolate1件: Levomefolic acid1件: D09353 --1件: 6
12B: 2 dosis----1件: 97
13Bacille Calmette-Guerin vaccine----1件: 13
14Bacille of Calmette-Guerin----1件: 13
15Background PAH Therapy----1件: 86
16Baclofen1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬8件: 2, 10, 13, 18, 65, 70, 149, 206
17Baclofen (baclofen Tab. 10mg) treatment1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 70
18Baclofen 20 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
19Baclofen ER Capsules (GRS) 10 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
20Baclofen ER Capsules (GRS) 20 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
21Baclofen ER Capsules (GRS) 30mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
22Baclofen ER Capsules (GRS) 40mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
23Baclofen ER Capsules (GRS) 50 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
24Baclofen IR1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
25Baclofen Tablets USP1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
26Baclofen Tablets USP 10 mg1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 13
27BACLOFENE----1件: 10
28Bacteriophage----1件: 65
29Bacteriophage preparation----1件: 96
30Bacteriotherapy----2件: 96, 97
31Bactrim1件: Trimethoprim1件: D00145 --1件: 299
32BAF312----2件: 13, 50
33BAF312 0,25 mg tablet----1件: 13
34BAF312 0,5 mg tablet----1件: 50
35BAF312 0.25 mg----1件: 50
36BAF312 0.25 mg tablet----1件: 50
37BAF312 0.25mg tablet----1件: 50
38BAF312 0.5 mg----1件: 50
39BAF312 0.50 mg----1件: 50
40BAF312 1 mg----1件: 50
41BAF312 1 mg tablet----2件: 13, 50
42BAF312 1mg----1件: 50
43BAF312 1mg tablet----1件: 50
44BAF312 2 mg----1件: 50
45BAF312 2 mg tablet----1件: 50
46BAF312 2mg----1件: 50
47BAF312 4 mg tablet----1件: 13
48BAF312 4mg tablet----1件: 50
49BAF312 5 mg tablet----1件: 50
50BAF312 hemifumarate----2件: 13, 50
51BAF312A----1件: 13
52BAF312X----1件: 50
53Bafiertam1件: Monomethyl fumarate1件: D11492 --1件: 13
54Baked Milk1件: Cow milk---1件: 98
55Balance1件: Isoxaflutole---5件: 6, 11, 46, 81, 149
56Balanced diet----1件: 49
57Balsalazide1件: Balsalazide1件: D07488 --1件: 97
58Balsalazide Disodium1件: Balsalazide1件: D07488 --1件: 97
59Baminercept1件: Baminercept1件: D08866 1件: LTB 💬3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬4件: 13, 46, 53, 97
60Baminercept alfa1件: Baminercept1件: D08866 1件: LTB 💬3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 46
61Baminercept alfa (BG9924)1件: Baminercept1件: D08866 1件: LTB 💬3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 46
62Bardoxolone1件: Bardoxolone1件: D09584 --7件: 66, 67, 84, 85, 86, 218, 222
63Bardoxolone methyl2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--7件: 66, 67, 84, 85, 86, 218, 222
64Bardoxolone methyl 10 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
65Bardoxolone methyl 15 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
66Bardoxolone methyl 20 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
67Bardoxolone methyl 5 mg2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
68Bardoxolone methyl capsules2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--4件: 66, 67, 86, 222
69Bardoxolone methyl oral capsule2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 67
70BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester2件: Bardoxolone,
Bardoxolone methyl		2件: D09584 ,
D09585 		--1件: 86
71Bardoxolone Metile1件: Bardoxolone1件: D09584 --1件: 67
72Baricinitib----1件: 49
73Baricitinib1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
74Baricitinib 2 MG1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬2件: 46, 53
75Baricitinib 2 MG [Olumiant]1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 162
76Baricitinib 4 MG1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
77Baricitinib treatment1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
78Baricitinib, olumiant®1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
79Barley1件: Barley---1件: 74
80BARNASCAN----1件: 88
81Barzolvolimab----1件: 98
82Bascial prescription plus or minus herbs depend on symptoms----1件: 97
83Baseline disease modifying therapies (DMTs)----1件: 13
84Baseline Treatment----1件: 13
85Basiliximab1件: Basiliximab1件: D03058 1件: IL2RA 💬11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬5件: 2, 50, 97, 222, 228
86Basimglurant1件: Basimglurant1件: D10864 --1件: 158
87BASSADO----1件: 23
88BASSADO 10CPS 100MG----1件: 23
89BAT1406----1件: 271
90BAT1806----1件: 46
91BAT1806 injection----1件: 46
92BAT4406F----1件: 13
93Batoclimab1件: Batoclimab1件: D11983 1件: FCGRT 💬-2件: 11, 14
94Batoclimab 340 mg SC bi-weekly1件: Batoclimab1件: D11983 1件: FCGRT 💬-1件: 11
95Batoclimab 340 mg SC weekly1件: Batoclimab1件: D11983 1件: FCGRT 💬-2件: 11, 14
96Batoclimab 680 mg SC weekly1件: Batoclimab1件: D11983 1件: FCGRT 💬-1件: 11
97Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly1件: Batoclimab1件: D11983 1件: FCGRT 💬-1件: 14
98Bavisant1件: Bavisant1件: D09870 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
99Bavisant dihydrochloride monohydrate1件: Bavisant1件: D09870 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
100BAVISANT HYDROCHLORIDE MONOHYDRATE1件: Bavisant1件: D09870 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
101Bawei Shenqi Pill----1件: 271
102BAX 111----1件: 288
103BAX111----1件: 288
104BAX930----1件: 64
105BAX930 - RECOMBINANT HUMAN ADAMTS13----1件: 64
106BAX930 or SHP655----1件: 64
107BAX930 or SHP655 or TAK755----1件: 64
108BAY 59-7939----1件: 210
109BAY 63-2521----2件: 86, 88
110BAY 63-2521 0.06 %----1件: 86
111BAY 63-2521 0.3 %----1件: 86
112BAY 63-2521 coated tablets 0.5 mg----2件: 86, 88
113BAY 63-2521 coated tablets 1 mg----2件: 86, 88
114BAY 63-2521 coated tablets 1.5 mg----2件: 86, 88
115BAY 63-2521 coated tablets 2 mg----2件: 86, 88
116BAY 63-2521 coated tablets 2.5 mg----2件: 86, 88
117BAY 63-2521 IR coated tablet 1.0 mg----1件: 88
118BAY 63-2521 IR coated tablet 1.5 mg----1件: 88
119BAY 63-2521 IR coated tablet 2.0 mg----1件: 88
120BAY 63-2521 IR coated tablet 2.5 mg----1件: 88
121BAY 63-2521 IR tablet 0.5 mg----1件: 88
122BAY 63-2521 IR tablet 1.0 mg----1件: 88
123BAY 63-2521 IR tablet 1.5 mg----1件: 88
124BAY 63-2521 IR tablet 2.0 mg----1件: 88
125BAY 63-2521 IR tablet 2.5 mg----1件: 88
126BAY 63-2521 IR tablets 0.5 mg----1件: 86
127BAY 63-2521 IR tablets 1 mg----1件: 86
128BAY 63-2521 IR tablets 1.0 mg----1件: 86
129BAY 63-2521 IR tablets 1.5 mg----1件: 86
130BAY 63-2521 IR tablets 2.0 mg----1件: 86
131BAY 63-2521 IR tablets 2.5 mg----1件: 86
132BAY 63-2521 Tablet----1件: 86
133BAY 63-2521 tablets 0.5 mg----2件: 86, 88
134BAY 63-2521 tablets 1 mg----2件: 86, 88
135BAY 63-2521 tablets 1.5 mg----2件: 86, 88
136BAY 63-2521 tablets 2 mg----2件: 86, 88
137BAY 63-2521 tablets 2.5 mg----2件: 86, 88
138BAY 79-4998----1件: 13
139BAY 85-8501----1件: 299
140BAY q 3939----1件: 299
141Bay Q 6256----1件: 86
142BAY1237592----2件: 86, 88
143BAY63-2521----3件: 51, 86, 299
144BAY85-8501----1件: 299
145BAY86-5046----1件: 13
146BAY86-5046_Interferon-beta-1b----1件: 13
147BAYQ3939----1件: 299
148Bazedoxifene1件: Bazedoxifene---1件: 13
149Bazedoxifene Acetate2件: Acetate,
Bazedoxifene		---1件: 13
150BBP-418----1件: 113
151BBP-671----2件: 245, 246
152BBP-8121件: BBP-812---1件: 307
153BBR 2778----2件: 11, 13
154BBT-401-1S----1件: 97
155BBT-401-1S, Multiple doses----1件: 97
156BBT-401-1S, Single dose----1件: 97
157BBT-877----1件: 85
158BBT-877, Multiple doses----1件: 85
159BBT-877, Single dose----1件: 85
160BCD-033 (interferon beta 1a)2件: Human interferon beta,
Interferon beta-1a		1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
161BCD-054 180 mcg----1件: 13
162BCD-054 240 mcg----1件: 13
163BCD-055----2件: 46, 271
164BCD-063----1件: 13
165BCD-085----2件: 93, 271
166BCD-089----1件: 46
167BCD-089, 162 mg, s/c, q2w----1件: 46
168BCD-089, 162 mg, s/c, qw----1件: 46
169BCD-132----1件: 13
170BCD-132, 125 mg----1件: 13
171BCD-132, 500 mg----1件: 13
172BCD-148----1件: 62
173BCG----1件: 299
174BCG TICE Vaccine----1件: 299
175BCG20-0134----1件: 13
176BCX9930----3件: 62, 66, 222
177BCX9930 hydrochloride----3件: 62, 66, 222
178BCX9930 monotherapy----1件: 62
179BD----2件: 28, 56
180BDMARD----1件: 46
181BDMARD treatment----1件: 271
182BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)5件: Abatacept,
Adalimumab,
Etanercept,
Golimumab,
Infliximab		5件: D00742 ,
D02597 ,
D02598 ,
D03203 ,
D04358 		4件: CD80,
CD86,
LTA,
TNF 💬		74件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬1件: 46
183BEAM Regimen----1件: 13
184Bean1件: Bean---1件: 96
185Beclometasone----1件: 97
186Beclometasone dipropionate1件: Beclomethasone dipropionate1件: D00689 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 85, 97
187Beclomethasone dipropionate1件: Beclomethasone dipropionate1件: D00689 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 97, 98
188Beclomethasone diproprionate----1件: 97
189Bee venom----1件: 6
190Beetainterferoni -1a----1件: 13
191Beetroot juice----2件: 67, 86
192BEFIRADOL----1件: 6
193Befizal----1件: 94
194BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée----1件: 94
195Begelomab1件: Begelomab---1件: 50
196Belantamab mafodotin1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
197Belantamab mafodotin 1.9 mg/kg (8 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
198Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
199Belantamab mafodotin 2.5 mg/kg (4 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
200Belantamab mafodotin 2.5 mg/kg (6 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
201Belantamab mafodotin 2.5 mg/kg (8 weeks)1件: Belantamab mafodotin1件: D11595 10件: TNFRSF17,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		12件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬1件: 28
202Belatacept1件: Belatacept1件: D03222 2件: CD80,
CD86 💬		13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 46
203Belcesiran----1件: 231
204BELIMUMAB1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300
205Belimumab 1 mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49
206Belimumab 10 mg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 222
207Belimumab 10 mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬3件: 43, 46, 49
208Belimumab 10 mg/kg plus standard therapy1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
209Belimumab 100 mg SC1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
210Belimumab 10mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
211Belimumab 200 mg SC1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
212Belimumab 200 mg/mL1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
213Belimumab 4 mg/kg1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49
214Belimumab for IV1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
215Belimumab for SC1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
216Belimumab in SLE patients / Rituximab in RA patients2件: Belimumab,
Rituximab		2件: D02994 ,
D03068 		2件: MS4A1,
TNFSF13B 💬		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49
217Belimumab Injection1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
218Belimumab Injection [Benlysta]1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
219Belimumab or benlysta1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
220Belimumab plus Early Vaccination1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
221Belimumab plus Late Vaccination1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
222Beloranib1件: Beloranib---1件: 193
223Belumosudil1件: Belumosudil1件: D11815 1件: ROCK2 💬21件: Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬2件: 51, 85
224Belumosudil (KD025)1件: Belumosudil1件: D11815 1件: ROCK2 💬21件: Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
225BEN-2001----1件: 6
226Benazepril1件: Benazepril1件: D07499 1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬4件: 49, 57, 218, 224
227Benazepril hydrochloride 10 milligram (mg) Tab1件: Benazepril1件: D07499 1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬1件: 218
228Benazepril Hydrochloride Tablets1件: Benazepril1件: D07499 1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬1件: 224
229Benazepril Pill1件: Benazepril1件: D07499 1件: ACE 💬6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬1件: 49
230Benazepril, Valsartan and Fluvastatin3件: Benazepril,
Fluvastatin,
Valsartan		3件: D00400 ,
D07499 ,
D07983 		3件: ACE,
AGTR1,
HMGCR 💬		22件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Bile secretion, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Terpenoid backbone biosynthesis, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 218
231Bendamustine1件: Bendamustine1件: D07501 --2件: 28, 61
232BENDAMUSTINE HYDROCHLORIDE1件: Bendamustine1件: D07501 --1件: 61
233Bendamustine, Rituximab2件: Bendamustine,
Rituximab		2件: D02994 ,
D07501 		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61
234BENDROFLUMETHIAZIDE1件: Bendroflumethiazide1件: D00650 1件: SLC12A3 💬-1件: 67
235Benepali1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
236Benerva----1件: 8
237Benlysta1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬5件: 43, 49, 53, 66, 222
238Benlysta (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬4件: 11, 49, 53, 222
239BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 53
240Benlysta 400 mg powder for concentrate for solution for infusion1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 43, 49
241Benlysta 400 mg powder for concentrate for solution for infusions1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
242Benlysta 400mg polvere per concentrato per soluzione per infusione1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 43
243BENLYSTA? (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
244Benlysta®1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 49, 222
245BENLYSTA® (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬3件: 11, 66, 222
246BENLYSTA™ (belimumab)1件: Belimumab1件: D03068 1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 49
247Benralizumab1件: Benralizumab1件: D09874 1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299
248BENSERAZIDE1件: Benserazide1件: D03082 1件: DDC 💬9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
249BENSERAZIDE HYDROCHLORIDE1件: Benserazide1件: D03082 1件: DDC 💬9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬1件: 6
250Benzbromaron----1件: 86
251Benzbromaron AL----1件: 86
252BENZBROMARONE1件: Benzbromarone1件: D01056 1件: SLC22A12 💬-1件: 86
253Benzimidazole1件: Benzimidazole---1件: 46
254Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole1件: Benzimidazole---1件: 46
255Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole1件: Benzimidazole---1件: 46
256Benznidazole1件: Benznidazole1件: D02489 --1件: 65
257Benzofuran1件: Benzofuran---1件: 6
258Benzoic acid1件: Benzoic acid1件: D00038 --1件: 51
259Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)2件: Alanine,
Tyrosine		2件: D00012 ,
D00022 		--1件: 298
260Bepranemab----1件: 5
261Berachin----1件: 6
262Beraprost1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
263Beraprost Sodium1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
264Beraprost Sodium 314d Modified Release Tablets1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
265Beraprost Sodium Modified Release1件: Beraprost1件: D02720 1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86
266Berberine1件: Berberine---2件: 97, 265
267Berberine Chloride2件: Berberine,
Chloride ion		---1件: 97
268BERMEKIMAB1件: Bermekimab1件: D11253 1件: IL1A 💬21件: AGE-RAGE signaling pathway in diabetic complications, Alzheimer disease, Cellular senescence, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Inflammatory bowel disease, Influenza A, Leishmaniasis, MAPK signaling pathway, Measles, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Tuberculosis, Type I diabetes mellitus 💬1件: 51
269Bertilimumab----2件: 97, 162
270Best Available Therapy (BAT)----1件: 13
271Best Medical Treatment----1件: 6
272Best médical treatment----1件: 6
273Best Supportive Care (BSC)----1件: 331
274Beta carotene1件: Beta carotene1件: D03101 --1件: 96
275Beta carotene from Dunaliella algae1件: Beta carotene1件: D03101 --1件: 96
276Beta Hydroxybutyrate Ester----1件: 2
277Beta-1,3/1,6-D-Glucan----1件: 97
278Beta-1b interferoni----1件: 13
279Beta-Adrenergic cocktail----1件: 299
280Beta-Alanine2件: Alanine,
beta-Alanine		2件: D00012 ,
D07561 		--1件: 13
281Beta-alanine supplementation2件: Alanine,
beta-Alanine		2件: D00012 ,
D07561 		--1件: 13
282Beta-Carotene1件: Beta carotene1件: D03101 --1件: 13
283Beta-cyclodextrin1件: Betadex1件: D02401 --1件: 19
284Beta-Galactosidase1件: Tilactase1件: D03348 --1件: 19
285Beta-hydroxybuturate esters----1件: 256
286Beta-Interferon----1件: 13
287Beta-lactam antibiotic----1件: 299
288Beta-Mercaptoethylamine1件: Cysteamine1件: D03634 --1件: 19
289Beta-mercaptoethylamine Hydrochloride & 2-aminoethanethiol Hydrochloride1件: Cysteamine1件: D03634 --1件: 19
290BETACAROTENE1件: Beta carotene1件: D03101 --1件: 13
291BETAFERON1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
292BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
293BETAFERON 250 mcg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
294Betaferon 250 microgram/ml1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
295Betaferon 250 microgram/ml, powder and solvent for solution for injection1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
296Betaferon 250 microgram/mL, powder and solvent for solution for injection.1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
297Betaferon 250 microgramos----1件: 13
298Betaferon 250mcg----1件: 13
299Betaferon 250µg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
300BETAFERON 500 mcg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
301Betaferon 500 µg----1件: 13
302Betaferon 500mcg----1件: 13
303Betaferon 500µg1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
304BETAFERON SC 15F 0,25MG 15SIR1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
305BETAFERON*15CONFEZ 0,25MG/ML+1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
306Betaferon/Betaseron----1件: 13
307Betaferon®1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
308BETAFERON® (interferon beta-1b)2件: Human interferon beta,
Interferon beta-1b		1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
309Betaine1件: Betaine1件: D07523 --2件: 201, 337
310Betaloc ZOK 100, 95 mg----1件: 113
311Betaloc ZOK 25, 23,75 mg----1件: 113
312Betamethasone1件: Betamethasone1件: D00244 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬8件: 2, 28, 46, 65, 83, 90, 96, 235
313BETAMETHASONE ACIBUTATE1件: Betamethasone1件: D00244 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46
314Betamethasone Oral Solution Period 1 and Period 21件: Betamethasone1件: D00244 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 65
315Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days3件: Acetate,
Betamethasone,
Phosphate ion		1件: D00244 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 2
316Betamethasone solution as intramuscular injection Period 1 and Period 21件: Betamethasone1件: D00244 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 65
317Betaquik MCT supplement----1件: 6
318Betaseron1件: Interferon beta-1b1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
319Betaseron (Interferon beta-1b, BAY86-5046)2件: Human interferon beta,
Interferon beta-1b		1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
320Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG2件: Human interferon beta,
Interferon beta-1b		1件: D00746 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
321Bethanechol1件: Bethanechol---1件: 98
322Bethkis----1件: 299
323Bevacizumab1件: Bevacizumab1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬6件: 13, 34, 85, 87, 227, 280
324Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)2件: Bevacizumab,
Imatinib		2件: D06409 ,
D08066 		4件: ABL1,
KIT,
PDGFRA,
VEGFA 💬		45件: AGE-RAGE signaling pathway in diabetic complications, Acute myeloid leukemia, Axon guidance, Bladder cancer, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Glioma, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pancreatic cancer, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway, Viral myocarditis 💬1件: 87
325Bevacizumab (Genitical Recombination)1件: Bevacizumab1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 34
326BEVACIZUMAB ZIRCONIUM ZR-892件: Bevacizumab,
Bevacizumab zirconium Zr-89		1件: D06409 1件: VEGFA 💬24件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬1件: 34
327Bevacuzimab spray----1件: 227
328Bevantolol1件: Bevantolol---1件: 8
329BEVANTOLOL HYDROCHLORIDE1件: Bevantolol---1件: 8
330Bexarotene1件: Bexarotene1件: D03106 3件: RXRA,
RXRB,
RXRG 💬		17件: Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬2件: 13, 75
331Bexotegrast----1件: 94
332Bexsero1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---6件: 11, 13, 61, 62, 66, 222
333BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---1件: 62
334BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---1件: 66
335BEXSERO – Sospensione iniettabile – Siringa preriempita1件: Neisseria meningitidis serogroup b nhba fusion protein antigen---2件: 61, 62
336Bezafibrat----1件: 93
337Bezafibrat Genericon retard 400 mg----1件: 93
338Bezafibrate1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬7件: 20, 93, 94, 160, 296, 316, 324
339Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy2件: Bezafibrate,
Ursodeoxycholic acid		2件: D00734 ,
D01366 		2件: NR1H4,
PPARA 💬		11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 94
340Bezafibrate (drug)1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 316
341Bezafibrate (INN 3968)1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 324
342Bezafibrate 200 MG1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
343Bezafibrate 200 MG Oral Tablet1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
344Bezafibrate 400 MG1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
345Bezafibrate IR1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
346Bezafibrate SR1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
347Bezafibrate, Beza, BZF, Bezalip1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
348Bezafibrate, Beza, BZF, Bezalip mono1件: Bezafibrate1件: D01366 1件: PPARA 💬10件: Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93
349Bezafilbrate IR----1件: 93
350Bezalip----3件: 93, 94, 160
351Bezalip mono----1件: 93
352Bezalip Retard----1件: 160
353Bezlotoxumab1件: Bezlotoxumab1件: D10453 --2件: 96, 97
354BF 2.649----1件: 6
355BF 2.649 10 mg----1件: 6
356BF 2.649 20 mg----1件: 6
357BF 2.649 40 mg----1件: 6
358BF 2.649 5 mg----1件: 6
359BF2.649----1件: 6
360BF2.649 (Pitolisant)1件: Pitolisant1件: D10749 1件: HRH3 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6
361BG-12 120----1件: 13
362BG00002----1件: 13
363BG00002 (natalizumab)1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
364BG00002-E (natalizumab high titer)1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
365BG00011----1件: 85
366BG00012----2件: 13, 46
367BG00012 (DMF)----1件: 13
368BG00012 (DMF) (Tecfidera®.)----1件: 13
369BG0002 (natalizumab)1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
370BG9418 (interferon beta 1-a)2件: Human interferon beta,
Interferon beta-1a		1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
371BG9418 (interferon beta-1a)2件: Human interferon beta,
Interferon beta-1a		1件: D04554 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬2件: 13, 97
372BG9924----2件: 46, 97
373BGC20-0134----1件: 13
374BGG492----1件: 13
375BGJ398----1件: 238
376BGJ398 (also known as BBP-831)----1件: 276
377BGP-014----1件: 97
378BGP-014 Capsules----1件: 97
379BGX-0214----1件: 46
380BH4----5件: 51, 86, 124, 240, 299
381BH4 20mg----1件: 299
382BH4 5mg----1件: 299
383BHP001----1件: 19
384BHT----1件: 13
385BHT-3009----1件: 13
386BHT-3009 0.5 mg----1件: 13
387BHT-3009 1.5 mg----1件: 13
388BHT-3009-01----1件: 13
389BHV-0223----1件: 2
390BHV-3241----1件: 17
391BHV-4157----1件: 17
392BHV3241, verdiperstat1件: Verdiperstat1件: D11684 1件: MPO 💬5件: Acute myeloid leukemia, Drug metabolism - other enzymes, Neutrophil extracellular trap formation, Phagosome, Transcriptional misregulation in cancer 💬1件: 17
393BI 1015550----1件: 85
394BI 1015550 18 mg Film Coated Tablet----1件: 85
395BI 1015550 9 mg Film Coated Tablet----1件: 85
396BI 1265162----1件: 299
397BI 1265162 10 µg----1件: 299
398BI 1265162 100 µg----1件: 299
399BI 1265162 25 µg----1件: 299
400BI 1265162 50 µg----1件: 299
401BI 443651----1件: 299
402BI 655064----1件: 46
403BI 655064 high dose----1件: 46
404BI 655064 low dose----1件: 46
405BI 655064 medium dose----1件: 46
406BI 655066----2件: 96, 271
407BI 655066 10 mg/ml----1件: 96
408BI 655066 90 mg/ml----2件: 96, 271
409BI 655130----3件: 37, 96, 97
410BI 685509----1件: 51
411BI 695500----1件: 46
412BI 695501----2件: 46, 96
413BI 695501 Autoinjector----1件: 46
414BI 695501 Prefilled syringe----1件: 46
415BI 705564----1件: 49
416BI 706321----1件: 96
417BI 730357----1件: 271
418BI 764198----1件: 222
419BI-Sifrol®----1件: 6
420BI655130----1件: 37
421BI706321----1件: 96
422BIA1件: BIA---2件: 6, 86
423BIA 3-2021件: BIA---1件: 6
424BIA 3-202 (200 mg)1件: BIA---1件: 6
425BIA 5-10581件: BIA---1件: 86
426BIA 6-5121件: BIA---1件: 6
427BIA 6-512 100 mg1件: BIA---1件: 6
428BIA 6-512 100 mg dose1件: BIA---1件: 6
429BIA 6-512 200 mg dose1件: BIA---1件: 6
430BIA 6-512 25 mg1件: BIA---1件: 6
431BIA 6-512 25 mg dose1件: BIA---1件: 6
432BIA 6-512 400 mg1件: BIA---1件: 6
433BIA 6-512 50 mg dose1件: BIA---1件: 6
434BIA 9-10671件: BIA---1件: 6
435BIA 9-1067 (test)1件: BIA---1件: 6
436BIA 9-1067 15 mg1件: BIA---1件: 6
437BIA 9-1067 25 mg1件: BIA---1件: 6
438BIA 9-1067 30 mg1件: BIA---1件: 6
439BIA 9-1067 5 mg1件: BIA---1件: 6
440BIA 9-1067 micronized1件: BIA---1件: 6
441BIA 9-1067 non-micronized1件: BIA---1件: 6
442BIA-5-10581件: BIA---1件: 86
443BIAP----2件: 46, 97
444Biaxin ( clarithromycin)1件: Clarithromycin1件: D00276 --1件: 299
445BIBF 1120----2件: 51, 85
446BIBF 1120 ES----1件: 85
447BIBF1120----1件: 85
448BIBR 796 BS----1件: 46
449BIBR 796 BS, 20 mg----1件: 96
450BIBR 796 BS, 5 mg----1件: 96
451Bicain spinal----1件: 46
452Bicarbonate Ringer's solution----1件: 296
453Bif195 capsules----1件: 96
454Bifico----1件: 291
455Bifidobacterium breve1件: Bifidobacterium breve---1件: 97
456Bifidobacterium infantis1件: Bifidobacterium longum infantis---2件: 96, 97
457Bifidobacterium infantis 356241件: Bifidobacterium longum infantis---2件: 96, 97
458BIIB 017----1件: 13
459BIIB014----1件: 6
460BIIB017----1件: 13
461BIIB017 (Peginterferon beta-1a)1件: Peginterferon beta-1a1件: D10483 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13
462BIIB019----1件: 13
463BIIB019 (Daclizumab High Yield Process)1件: Daclizumab1件: D03639 1件: IL2RA 💬11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13
464BIIB019 (Daclizumab)1件: Daclizumab1件: D03639 1件: IL2RA 💬11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13
465BIIB023----1件: 46
466BIIB033----1件: 13
467BIIB033 (ANTI-LINGO)----1件: 13
468BIIB033 (ANTI-LINGO) - EV Substance Code SUB118957----1件: 13
469BIIB033 (opicinumab)1件: Opicinumab1件: D11767 1件: LINGO1 💬-1件: 13
470BIIB041----1件: 13
471BIIB041 (fampridine)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
472BIIB041 (Fampridine-SR)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
473BIIB041 (PR Fampridine)1件: Dalfampridine1件: D04127 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13
474BIIB050 / KNS-760704----1件: 2
475BIIB050/KNS-760704----1件: 2
476BIIB054----1件: 6
477BIIB057----1件: 46
478BIIB059----1件: 49
479BIIB059 (litifilimab)----1件: 49
480BIIB061----1件: 13
481BIIB067----1件: 2
482BIIB067 (ISIS666853)----1件: 2
483BIIB067 (Tofersen)1件: Tofersen1件: D11811 1件: SOD1 💬8件: Amyotrophic lateral sclerosis, Chemical carcinogenesis - reactive oxygen species, Huntington disease, Longevity regulating pathway - multiple species, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Peroxisome, Prion disease 💬1件: 2
484BIIB078----1件: 2
485BIIB092----3件: 5, 7, 127
486BIIB094----1件: 6
487BIIB100----1件: 2
488BIIB105----1件: 2
489BIIB111----1件: 90
490BIIB112----1件: 90
491BIIB122----1件: 6
492BIIB133----1件: 13
493BIIL 283 BS (Amelubent)----1件: 299
494BIIL 284 BS high dose----1件: 46
495BIIL 284 BS low dose----1件: 46
496BIIL 284 BS medium dose----1件: 46
497BIIL 284 BS, high dose----1件: 299
498BIIL 284 BS, high dose, adult patients----1件: 299
499BIIL 284 BS, high dose, pediatric patients----1件: 299
500BIIL 284 BS, low dose----1件: 299
501BIIL 284 BS, low dose, adult patients----1件: 299
502BIIL 284 BS, low dose, pediatric patients----1件: 299
503BIIL 284 BS, medium dose, adult patients----1件: 299
504BIIL 284 BS, medium dose, pediatric patients----1件: 299
505Biklin----1件: 299
506Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus----1件: 6
507Bilateral transforaminal epidural steroid injections----1件: 70
508BIM 23014----1件: 67
509Bimagrumab1件: Bimagrumab1件: D10620 2件: ACVR2A,
ACVR2B 💬		4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 15
510BIMEKIZUMAB1件: Bimekizumab1件: D11550 2件: IL17A,
IL17F 💬		6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬3件: 46, 97, 271
511Binimetinib1件: Binimetinib1件: D10604 2件: MAP2K1,
MAP2K2 💬		89件: Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬1件: 34
512BINOCRIT*1SIR 40000UI/1ML1件: Erythropoietin---1件: 18
513Binyrebarkhormon----1件: 46
514Binyrebsrkhormon----1件: 46
515Bio-25 probiotic----1件: 299
516Bio-enhanced Curcumin Soft Gelatin Capsule2件: Curcumin,
Gelatin		2件: D00115 ,
D06892 		--1件: 97
517BIO101----1件: 113
518Biobanking with genetic analysis----3件: 13, 51, 56
519Biocarn----1件: 3
520Biodmards----1件: 46
521Biologic Agents----1件: 46
522Biologic DMARD----2件: 46, 271
523Biologic DMARDs----1件: 107
524Biologic/targeted therapy----1件: 46
525Biologic: IC14 (monoclonal antibody against human CD14)----1件: 2
526Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)1件: Human immunoglobulin G---1件: 14
527Biological agents----1件: 46
528Biological disease-modifying antirheumatic drugs (bDMARDs)----1件: 46
529Biological DMARDs----2件: 86, 107
530Biological Drug----3件: 46, 96, 97
531Biological samples----1件: 13
532Biological sampling----1件: 65
533Biological samplings----1件: 96
534Biological/Vaccine: Allogeneic HB-adMSCs1件: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins---1件: 6
535Biological: Benralizumab, Biological: Placebo to Mepolizumab2件: Benralizumab,
Mepolizumab		2件: D04923 ,
D09874 		2件: IL5,
IL5RA 💬		13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 44
536Biological: Mepolizumab, Biological: Placebo to Benralizumab2件: Benralizumab,
Mepolizumab		2件: D04923 ,
D09874 		2件: IL5,
IL5RA 💬		13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 44
537Biologically active human fecal microbiota----1件: 97
538Biologics----3件: 46, 96, 97
539Biomarker identification in Parkinson disease----1件: 6
540BION-1301 Multiple Doses----1件: 66
541BION-1301 Single Dose----1件: 66
542BIOOPA dressing----1件: 36
543Biopsies----1件: 97
544Biopsy----1件: 51
545Biopsy of the labial salivary gland----1件: 53
546Biosimilar----4件: 46, 96, 97, 271
547Biosimilar adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 107
548Biosimilar Etanercept1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 107
549Biosimilar Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬3件: 46, 96, 97
550Biosimilar product to adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
551Biostate----1件: 288
552Biostate®----1件: 288
553BIOTIN1件: Biotin1件: D00029 --5件: 2, 8, 10, 13, 20
554Biotina1件: Biotin1件: D00029 --2件: 8, 13
555BIRB 796 BS, high dose----1件: 46
556BIRB 796 BS, low dose----1件: 46
557BIRCH BARK EXTRACT1件: Birch bark extract---1件: 36
558BIRT 2584 XX----1件: 13
559BIRT 2584XX----1件: 13
560BIRTAMIMAB1件: Birtamimab1件: D11373 --1件: 28
561BIS-CHOLINE TETRATHIOMOLYBDATE2件: Choline,
Tetrathiomolybdate		1件: D07690 --1件: 171
562BIS-CHOLINE TETRATHIOMOLYBDATE, bis[(2-Hydroxyethyl)trimethylammonium] tetrathiomolybdate2件: Choline,
Tetrathiomolybdate		1件: D07690 --1件: 171
563Bisacodyl1件: Bisacodyl1件: D00245 --1件: 13
564BISOPROLOL1件: Bisoprolol1件: D02342 1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 58, 67, 86, 113
565Bisoprolol Fumarate1件: Bisoprolol1件: D02342 1件: ADRB1 💬11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 113
566Bisphosphonate treatment----2件: 113, 299
567Bisphosphonates----2件: 6, 274
568BITTER CANDYTUFT FRESH PLANT EXTRACT----1件: 97
569Bitterschleifenblume-ganzpflanze 1,5ml/10ml----1件: 97
570BIV009----2件: 61, 162
571Bivigam----1件: 65
572BIVV001 (rFVIIIFc-VWF-XTEN)----1件: 288
573BIVV009----1件: 61
574BIVV020----2件: 14, 61
575BL-7040----1件: 97
576BL-8040----1件: 60
577Bladder instillation with heparin/ lidocaine2件: Heparin,
Lidocaine		3件: D00358 ,
D07510 ,
D08127 		6件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬1件: 226
578Bladder instillation WITH triamcinolone acetonide1件: Triamcinolone1件: D00385 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 226
579Bladder instillation WITHOUT triamcinolone acetonide1件: Triamcinolone1件: D00385 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 226
580Bladder Instillations----1件: 226
581Bladder tissue of Interstitial Cystitis and normal bladder tissue----1件: 226
582Blarcamesine1件: Blarcamesine1件: D11383 6件: CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5,
SIGMAR1 💬		14件: Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬1件: 156
583BLD-2660----1件: 85
584Bleomycin1件: Bleomycin1件: D07535 --4件: 96, 278, 279, 280
585Bleomycin + Fibrovein1件: Bleomycin1件: D07535 --1件: 279
586Bleomycin Baxter1件: Bleomycin1件: D07535 --1件: 279
587Bleselumab1件: Bleselumab1件: D11357 1件: CD40 💬17件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis 💬1件: 222
588BLF----1件: 299
589BLI-1300 high dose----1件: 96
590BLI-1300 low dose----1件: 96
591Blinded (Avatrombopoag tablets)----1件: 63
592Blinded CDCA 250 mg TID1件: Chenodeoxycholic acid1件: D00163 1件: NR1H4 💬1件: Bile secretion 💬1件: 263
593Blisibimod1件: Blisibimod1件: D10311 --5件: 43, 44, 49, 63, 66
594Blisibimod Injection1件: Blisibimod1件: D10311 --1件: 66
595Blokium 50----1件: 167
596BLOKIUM 50 mg comprimidos----1件: 167
597Blood----1件: 46
598Blood and stools samples----1件: 96
599Blood and urine sampling----1件: 195
600Blood and/or skin biopsy----2件: 90, 301
601Blood assays----1件: 113
602Blood coagulation Factor VIII and vWF, human1件: Beroctocog alfa---1件: 288
603Blood coagulation factor XIII1件: Factor XIII (human)---1件: 51
604Blood collection----2件: 229, 271
605Blood draw----1件: 6
606Blood draw for the laboratory assessment----1件: 303
607Blood or Saliva Sample Collection----1件: 299
608Blood sample----20件: 8, 13, 46, 49, 51, 53, 61, 66, 84, 88, 96, 97, 107, 127, 235, 274, 280, 288, 294, 299
609Blood sample and environmental survey----1件: 2
610Blood sample collection----1件: 85
611Blood samples----9件: 13, 41, 51, 61, 97, 227, 240, 271, 280
612Blood sampling----5件: 13, 46, 49, 51, 96
613Blood Sampling and DNA collection----1件: 6
614Blood sampling for biological and genetic analysis----1件: 19
615Blood test----6件: 36, 51, 107, 113, 162, 299
616Blood tests----2件: 46, 263
617BLS-M221件: BLS-M22---1件: 113
618Bluefish1件: Bluefish---1件: 58
619BLZ945----1件: 2
620BM110----1件: 19
621BMDex----1件: 28
622BMMNC----1件: 13
623BMMNCs----1件: 90
624BMN 044----1件: 113
625BMN 044 IV 6 mg/kg----1件: 113
626BMN 044 IV 9 mg/kg----1件: 113
627BMN 044 SC 6 mg/kg----1件: 113
628BMN 0451件: BMN-045---1件: 113
629BMN 053----1件: 113
630BMN 110----1件: 19
631BMN 110 - Every Other Week----1件: 19
632BMN 110 - Weekly----1件: 19
633BMN 110 Every Other Week----1件: 19
634BMN 110 Weekly----1件: 19
635BMN 111----1件: 276
636BMN 165----1件: 240
637BMN 165 (rAvPAL-PEG)1件: Pegvaliase1件: D11077 1件: PAH 💬5件: Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬1件: 240
638BMN 190----1件: 19
639BMN 250----1件: 19
640BMN 307----1件: 240
641BMN 701----1件: 256
642BMN0531件: BMN-053---1件: 113
643BMN165 20mg/day----1件: 240
644BMN165 40mg/day----1件: 240
645BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)----1件: 19
646BMS 188667 (Abatacept)1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 13
647BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)5件: Digoxin,
Flurbiprofen,
Midazolam,
Montelukast,
Omeprazole		5件: D00298 ,
D00330 ,
D00455 ,
D00550 ,
D08229 		25件: ATP1A1,
ATP1A2,
ATP1A3,
ATP1A4,
ATP4A,
ATP4B,
CYSLTR1,
GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ,
PTGS1,
PTGS2 💬		49件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 46
648BMS-188667----9件: 46, 49, 53, 65, 96, 97, 107, 222, 271
649BMS-232632----1件: 265
650BMS-5829491件: BMS-582949---1件: 46
651BMS-582949 and Methotrexate2件: BMS-582949,
Methotrexate		1件: D00142 2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
652BMS-8173991件: BMS-817399---1件: 46
653BMS-9316991件: Lulizumab pegol---3件: 49, 53, 160
654BMS-936557----2件: 96, 97
655BMS-936557 (Anti-IP-10 Antibody)----1件: 96
656BMS-9454291件: Clazakizumab1件: D10312 --2件: 46, 96
657BMS-986004----1件: 63
658BMS-986004 1500 mg IV----1件: 63
659BMS-986004 225 mg IV----1件: 63
660BMS-986004 675 mg IV----1件: 63
661BMS-986004 75 mg IV----1件: 63
662BMS-9860201件: BMS-986020---2件: 51, 85
663BMS-986089----1件: 113
664BMS-986089-01 (RO7239361) , anti-myostatin----1件: 113
665BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL)----1件: 113
666BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL)----1件: 113
667BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL)----1件: 113
668BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL)----1件: 113
669BMS-986089-01 (RO7239361), anti-myostatin----1件: 113
670BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL)----1件: 113
671BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL)----1件: 113
672BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL)----1件: 113
673BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL)----1件: 113
674BMS-986089-01, Anti-myostatin----1件: 113
675BMS-9861041件: BMS-986104---1件: 46
676BMS-9861421件: BMS-986142---3件: 46, 53, 160
677BMS-986142 200mg1件: BMS-986142---1件: 46
678BMS-986142 350mg1件: BMS-986142---1件: 46
679BMS-986165----3件: 49, 96, 97
680BMS-986165 Capsule----1件: 49
681BMS-986165 Tablet----1件: 49
682BMS-986166----1件: 97
683BMS-9861681件: Gosuranemab1件: D11293 1件: MAPT 💬4件: Alzheimer disease, MAPK signaling pathway, Parkinson disease, Pathways of neurodegeneration - multiple diseases 💬1件: 5
684BMS-986184----1件: 97
685BMS-9861951件: Branebrutinib1件: D11478 1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬3件: 46, 49, 53
686BMS-986251----2件: 46, 271
687BMS-9862561件: Afimetoran1件: D11908 --1件: 49
688BMS-986256-06, TLR7/8 Antagonist1件: Afimetoran1件: D11908 --1件: 49
689BMS-986278----1件: 85
690BMS-986325----1件: 53
691BMS188667----1件: 46
692BMS986142----3件: 46, 53, 160
693BMS986165----2件: 96, 97
694BMS986168----1件: 5
695BMS986195----3件: 46, 49, 53
696BN82451B----1件: 8
697BN8251B----1件: 8
698BNJ441----1件: 66
699BNP----2件: 46, 58
700BNP blood sample test----1件: 58
701BNT162b2----7件: 13, 35, 46, 49, 50, 51, 107
702BNT162b2, Bivalent----7件: 13, 35, 46, 49, 50, 51, 107
703Bocidelpar1件: Bocidelpar1件: D12242 1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 113
704Bof-, Mazelen-, Rubellavaccin, poeder voor injectievloeistof----1件: 107
705Bone balance measurements1件: Isoxaflutole---1件: 81
706Bone marrow autologous mesenchymal stem cells transplantation----1件: 13
707Bone Marrow Concentrate----1件: 70
708Bone marrow derived mesenchymal stem cells----2件: 6, 60
709Bone Marrow Derived Mesenchymal Stem cells (MSCs)----1件: 96
710Bone marrow mesenchymal stem cells----1件: 85
711Bone marrow transplant----1件: 274
712Bone marrow-derived mesenchymal stem cells----1件: 298
713Bone marrow-derived mesenchymal stromal cells (MSCs)1件: Human Umbilical Cord Mesenchymal Stem Cells---1件: 274
714Bonefos1件: Clodronic acid1件: D03545 --1件: 274
715BoNT-A----1件: 6
716Bony Toxicity----1件: 34
717BOOST cells----1件: 274
718Boost VHC----1件: 299
719Boostrix1件: Clostridium tetani toxoid antigen (formaldehyde inactivated)---1件: 46
720Boostrix®1件: Clostridium tetani toxoid antigen (formaldehyde inactivated)---1件: 46
721Boots High Strength Garlic Odour Controlled1件: Garlic1件: D12020 --1件: 299
722BORAGE OIL1件: Borage oil---1件: 13
723BORAGE OIL 20% GLA1件: Borage oil---1件: 13
724Borage seed oil----1件: 46
725BORTEZOMIB1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬17件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331
726Bortezomib (Velcade®)1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 66
727Bortezomib Accord2件: Bortezomib,
Bortezomib D-mannitol		1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 28
728Bortezomib D-mannitol3件: Bortezomib,
Bortezomib D-mannitol,
Mannitol		2件: D00062 ,
D03150 		1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 28
729Bortezomib Injection1件: Bortezomib1件: D03150 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 64
730Bortezomib/dexamethasone2件: Bortezomib,
Dexamethasone		2件: D00292 ,
D03150 		2件: NR3C1,
PSMB5 💬		9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 283
731Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone2件: Bortezomib,
Dexamethasone		2件: D00292 ,
D03150 		2件: NR3C1,
PSMB5 💬		9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬1件: 28
732BOS161721----1件: 49
733Bosentan1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬10件: 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
734Bosentan (Tracleer)1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
735Bosentan 125 mg1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
736Bosentan 62.5 mg1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
737Bosentan administration1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
738Bosentan and Sildenafil2件: Bosentan,
Sildenafil		3件: D01227 ,
D07538 ,
D08514 		3件: EDNRA,
EDNRB,
PDE5A 💬		11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
739Bosentan group1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 51
740BOSENTAN MONOHIDRATO1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
741Bosentan monohydrat1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
742BOSENTAN MONOHYDRATE1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 51, 84, 86, 88
743BOSENTAN MYLAN1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 41
744Bosentan, Ambrisentan2件: Ambrisentan,
Bosentan		3件: D01227 ,
D07077 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
745Bosutinib1件: Bosutinib1件: D03252 2件: ABL1,
SRC 💬		49件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬2件: 2, 67
746Bosutinib (anhydrous)1件: Bosutinib1件: D03252 2件: ABL1,
SRC 💬		49件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬1件: 67
747Bosutinib (Phase 1 part)1件: Bosutinib1件: D03252 2件: ABL1,
SRC 💬		49件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬1件: 2
748Bosutinib (Phase 2 part)1件: Bosutinib1件: D03252 2件: ABL1,
SRC 💬		49件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬1件: 2
749BOSWELAN----1件: 13
750Boswellia Serrata1件: Indian frankincense---1件: 13
751Boswellia Serrata Extract1件: Indian frankincense---1件: 13
752Boswellia serrata extract PS0201Bo capsules1件: Indian frankincense---1件: 13
753Boswellic acids (BOSWELAN)----1件: 13
754Botaretigene Sparoparvovec1件: Botaretigene sparoparvovec---1件: 90
755Botox1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬7件: 2, 6, 13, 47, 51, 149, 226
756BOTOX 100 UNITES ALLERGAN (PR1)1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 2
757Botox 100 UNT Injection1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
758BOTOX 100U in normal saline1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 226
759BOTOX 200U in normal saline1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 226
760Botox injection1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬2件: 2, 47
761BOTOX®1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
762BOTOX® solution1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 51
763Botulinic toxin----1件: 36
764Botulinum A toxin----1件: 118
765Botulinum Neurotoxin----1件: 226
766Botulinum Toxin----3件: 6, 13, 149
767Botulinum toxin A1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬4件: 13, 51, 149, 226
768BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
769BOTULINUM TOXIN TYPE A1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149
770Botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 70
771Botulinum Toxin Type A 200U1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
772Botulinum Toxin Type A 300U1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 13
773Botulinum toxin type B1件: Botulinum toxin type B1件: D02735 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬3件: 2, 6, 51
774Botulinum toxin type B (2500 units / vial)1件: Botulinum toxin type B1件: D02735 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 51
775Botulinum toxin type B (Myobloc)1件: Botulinum toxin type B1件: D02735 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬2件: 2, 6
776Botulinum toxin(Botox)1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 51
777Botulinum Toxin: Xeomin1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 6
778Botulism Toxin Treatment----1件: 161
779Boulardii----2件: 96, 97
780Bovine intesastinal alkaline phosphatase (bIAP)1件: Alkaline Phosphatase---1件: 46
781Bovine intestinal alkaline phosphatase (BIAP)1件: Alkaline Phosphatase---1件: 97
782Bovine type I collagen1件: Bovine type I collagen---1件: 51
783Bovine-Calf Alkaline Phosphatase (BIAP)1件: Alkaline Phosphatase---1件: 97
784Bovine-Calf Alkaline Phosphatase BIAP1件: Alkaline Phosphatase---1件: 97
785BOW015----1件: 46
786BPA----1件: 88
787BPLG-003----1件: 78
788BPN14770----1件: 206
789BPN14770/ zatolmilast1件: Zatolmilast1件: D12173 1件: PDE4D 💬5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬1件: 206
790BPR277----1件: 160
791BPR277 ointment----1件: 160
792BPR277 ointment (controlled application)----1件: 160
793BPS-314d-MR----1件: 86
794BPS-MR----1件: 86
795BPS804----2件: 172, 274
796BPS804, UX143----1件: 274
797BPX-501----3件: 60, 285, 326
798BPX-501 cells----3件: 60, 285, 326
799BPX-501 T cells----4件: 65, 284, 285, 326
800BQ123----1件: 17
801BR-DIM----1件: 49
802BR9001----1件: 46
803BR900A----1件: 46
804BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML----1件: 299
805Bramitob----1件: 299
806BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML----1件: 299
807Bramitob 300mg/4ml Nebuliser Solution----1件: 299
808BRAMITOB*NEBUL 28F 300MG/4ML----1件: 299
809BRAMITOB*NEBUL 56F 300MG/4ML----1件: 299
810Bramitob® administered by PARI eFlow® rapid electronic nebulizer----1件: 299
811Bramitob® administered by PARI LC® PLUS nebulizer----1件: 299
812Branaplam1件: Branaplam1件: D12272 1件: SMN2 💬-2件: 3, 8
813Branebrutinib1件: Branebrutinib1件: D11478 1件: BTK 💬7件: B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬3件: 46, 49, 53
814BRAZIKUMAB1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97
815Brazikumab high dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
816Brazikumab Induction Dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97
817Brazikumab IV Infusion1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
818Brazikumab low dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
819Brazikumab Maintenance Dose1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬2件: 96, 97
820Brazikumab SC Injection1件: Brazikumab1件: D10912 1件: IL23A 💬9件: C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬1件: 96
821Break in L-carnitine treatment1件: Levocarnitine1件: D02176 --1件: 316
822BREDININ1件: Mizoribine1件: D01392 2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 46
823Bredinin tablet 150mg1件: Mizoribine1件: D01392 2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 46
824Bredinin tablet 50mg1件: Mizoribine1件: D01392 2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 46
825Brensocatib1件: Brensocatib1件: D12120 1件: CTSC 💬2件: Apoptosis, Lysosome 💬1件: 299
826Brensocatib 10 mg1件: Brensocatib1件: D12120 1件: CTSC 💬2件: Apoptosis, Lysosome 💬1件: 299
827Brensocatib 25 mg1件: Brensocatib1件: D12120 1件: CTSC 💬2件: Apoptosis, Lysosome 💬1件: 299
828Brentuximab1件: Brentuximab vedotin1件: D09587 10件: TNFRSF8,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		11件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬2件: 49, 51
829Brentuximab vedotin1件: Brentuximab vedotin1件: D09587 10件: TNFRSF8,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		11件: Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬2件: 49, 51
830Brepocitinib----2件: 49, 50
831Brepocitinib 25 mg----2件: 96, 97
832Brepocitinib 5 mg----2件: 96, 97
833Brepocitinib 5mg----1件: 96
834Brigatinib1件: Brigatinib1件: D10866 1件: ALK 💬3件: Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer 💬1件: 34
835Brimonidine1件: Brimonidine1件: D07540 3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬2件: 13, 90
836Brimonidine tartrate1件: Brimonidine1件: D07540 3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬2件: 13, 90
837Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System1件: Brimonidine1件: D07540 3件: ADRA2A,
ADRA2B,
ADRA2C 💬		2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬1件: 90
838Brineura1件: Cerliponase alfa1件: D10813 1件: TPP1 💬1件: Lysosome 💬1件: 19
839Brivaracetam1件: Brivaracetam1件: D08879 1件: SV2A 💬1件: ECM-receptor interaction 💬2件: 149, 309
840Brivaracetam 25 mg1件: Brivaracetam1件: D08879 1件: SV2A 💬1件: ECM-receptor interaction 💬1件: 309
841Brivaracetam 50 mg1件: Brivaracetam1件: D08879 1件: SV2A 💬1件: ECM-receptor interaction 💬1件: 309
842BRL-049653----1件: 46
843Broccoli1件: Broccoli---3件: 36, 97, 299
844Broccoli sprouts1件: Broccoli---1件: 299
845Brodalumab1件: Brodalumab1件: D10061 1件: IL17RA 💬3件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway 💬2件: 37, 51
846Brodalumab 210mg SC1件: Brodalumab1件: D10061 1件: IL17RA 💬3件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway 💬1件: 37
847BROMOCRIPTINE1件: Bromocriptine1件: D03165 2件: DRD2,
PRL 💬		12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬2件: 6, 74
848Bromocriptine and other dopamine agonists2件: Bromocriptine,
Dopamine		2件: D03165 ,
D07870 		6件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5,
PRL 💬		15件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
849Bromure d'Ipratropium1件: Ipratropium---1件: 86
850Bronchial mucus collection----1件: 299
851Bronchitol1件: Mannitol1件: D00062 --1件: 299
852Broncho-Vaxom1件: OM85---1件: 85
853Bronchoalveolar lavage fluid collection----1件: 229
854Bronchodilator Response----1件: 294
855BRV 2.5 mg----1件: 309
856BRV 25 mg----1件: 309
857BRV 50 mg----1件: 309
858BRX-345----2件: 2, 15
859Bryostatin 11件: Bryostatin 1---1件: 62
860BS01----1件: 90
861BSF 208075----1件: 86
862BSF 208075 or LU 208075----1件: 86
863BT----3件: 96, 97, 98
864BT-11----2件: 96, 97
865BT-11 (1000 mg)----1件: 97
866BT-11 (500 mg)----1件: 97
867BT-11 (Omilancor)----1件: 96
868BT-11 1,000 mg----1件: 96
869BT-11 1000mg----3件: 96, 97, 98
870BT-11 500 mg----2件: 96, 97
871BT-11 500mg----1件: 98
872BT-11 Active----2件: 96, 97
873BT051 200 mg----1件: 97
874BT051 3200 mg----1件: 97
875BT051 800 mg----1件: 97
876BT061----1件: 46
877BT061 (CD4 monoclonal antibody)----1件: 46
878BT063----1件: 49
879BT090----1件: 65
880BT524----1件: 65
881BT595----2件: 63, 65
882BT681----1件: 65
883BT971----1件: 46
884BTK Inhibitor----3件: 46, 53, 160
885BTRX-2460401件: BTRX-246040---1件: 6
886BTT-1023----1件: 46
887BTT1023----1件: 94
888BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product----1件: 94
889BTX-A1件: Botulinum toxin type A1件: D00783 1件: SNAP25 💬2件: Insulin secretion, Synaptic vesicle cycle 💬1件: 6
890Bucelipase alfa1件: Bucelipase alfa---1件: 299
891Bucillamine1件: Bucillamine1件: D01809 --1件: 46
892Buckwheat1件: Buckwheat---1件: 226
893Bucladesine1件: Bucladesine1件: D07546 16件: PDE10A,
PDE11A,
PDE1A,
PDE1B,
PDE1C,
PDE2A,
PDE3A,
PDE3B,
PDE4A,
PDE4B,
PDE4C,
PDE4D,
PDE7A,
PDE7B,
PDE8A,
PDE8B 💬		18件: Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 246
894Budenofalk----1件: 96
895Budenofalk 2mg rectal foam----1件: 97
896Budenofalk 3mg----2件: 93, 97
897Budenofalk 3mg gastro-resistant capsules----1件: 96
898Budenofalk 9mg gastro-resistant granules----1件: 96
899Budenofalk rectal foam----1件: 97
900Budenofalk® suppositories----1件: 97
901Budenofalk® suppositories (BUS)----1件: 97
902Budesonid----1件: 95
903BUDESONIDE1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬9件: 66, 93, 94, 95, 96, 97, 98, 228, 299
904Budesonide ( Zentacort Capsules 3mg )1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 96
905Budesonide (6 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
906Budesonide (9 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
907Budesonide 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
908Budesonide 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
909Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
910Budesonide 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
911Budesonide 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
912Budesonide 1 mg orodispersible tablets (BUL 1 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
913Budesonide 1mg orodispersible tablet twice daily1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
914Budesonide 2 mg orodispersible tablets (BUL 2 mg)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
915Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
916Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
917Budesonide 9 mg capsules, hard (BUX-PV)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
918Budesonide 9 mg prolonged-release capsule, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
919Budesonide 9 mg prolonged-release capsules, hard (BUX-PVII prototype)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
920Budesonide [0.4mg/ml] viscous suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
921Budesonide Gel1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
922Budesonide MMX1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
923Budesonide MMX 6 mg Tablet1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
924Budesonide MMX®1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
925Budesonide MMX® 6 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
926Budesonide MMX® 9 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
927Budesonide oral suspension1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
928Budesonide oral suspension [0.2 mg/ml]1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
929Budesonide Orodispersible Tablets (Jorveza)1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
930Budesonide plus Prevacid1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
931Budesonide-formoterol single inhaler2件: Budesonide,
Formoterol		2件: D00246 ,
D07990 		2件: ADRB2,
NR3C1 💬		9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 299
932Budesonide-MMX1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
933Budesonide-MMX®1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
934Budesonide-MMX® 6 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
935Budesonide-MMX® 9 mg1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
936Budesonide-MMX™1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97
937Budesonide/formoterol2件: Budesonide,
Formoterol		2件: D00246 ,
D07990 		2件: ADRB2,
NR3C1 💬		9件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 228
938BUET 0.5 mg----1件: 98
939BUET 1 mg----1件: 98
940BUET 1mg----1件: 98
941BUET 2mg----1件: 98
942BUL 0.5 mg----1件: 98
943BUL 1 mg----1件: 98
944BUMEKIZUMAB----1件: 46
945Bumetanide1件: Bumetanide1件: D00247 1件: SLC12A2 💬3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬2件: 6, 158
946Bumetanide white, oblong, scored tablet1件: Bumetanide1件: D00247 1件: SLC12A2 💬3件: Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬1件: 6
947Buntanetap----1件: 6
948BUPI5----1件: 53
949Bupivacaine1件: Bupivacaine1件: D07552 5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬8件: 46, 51, 53, 70, 96, 168, 226, 298
950BUPIVACAINE HYDROCHLORIDE1件: Bupivacaine1件: D07552 5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬2件: 46, 53
951Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)1件: Bupivacaine1件: D07552 5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 46
952Bupivacaine Injection 0.5%1件: Bupivacaine1件: D07552 5件: SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬1件: 168
953Bupivacaine, triamcinolone, and heparin (BTH)3件: Bupivacaine,
Heparin,
Triamcinolone		3件: D00385 ,
D07510 ,
D07552 		7件: NR3C1,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		5件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction 💬1件: 226
954Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine3件: Bupivacaine,
Clonidine,
Epinephrine		3件: D00095 ,
D00281 ,
D07552 		14件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 70
955Bupivacaine/epinephrine/dexamethasone3件: Bupivacaine,
Dexamethasone,
Epinephrine		3件: D00095 ,
D00292 ,
D07552 		15件: ADRA1A,
ADRA1B,
ADRA1D,
ADRA2A,
ADRA2B,
ADRA2C,
ADRB1,
ADRB2,
ADRB3,
NR3C1,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A 💬		16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 96
956Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml1件: Sufentanil1件: D05938 1件: OPRM1 💬3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 70
957Bupivicaine alone----1件: 298
958Bupizenge----1件: 53
959Bupleurum+Ginkgo1件: Ginkgo biloba---1件: 6
960Buprenorphine1件: Buprenorphine1件: D07132 2件: OPRK1,
OPRM1 💬		3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬2件: 46, 70
961Buprenorphine Transdermal Patch1件: Buprenorphine1件: D07132 2件: OPRK1,
OPRM1 💬		3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬1件: 46
962Bupropion1件: Bupropion1件: D07591 2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬5件: 8, 18, 21, 96, 171
963Bupropion & Citalopram2件: Bupropion,
Citalopram		2件: D07591 ,
D07704 		3件: SLC6A2,
SLC6A3,
SLC6A4 💬		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle 💬1件: 18
964Bupropion Hydrochloride1件: Bupropion1件: D07591 2件: SLC6A2,
SLC6A3 💬		7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 171
965Burlulipase1件: Burlulipase---1件: 299
966Burosumab1件: Burosumab1件: D10913 1件: FGF23 💬11件: Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬1件: 238
967BUSILVEX1件: Busulfan1件: D00248 --4件: 19, 36, 60, 65
968BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI1件: Busulfan1件: D00248 --2件: 19, 65
969Buspirone1件: Buspirone1件: D07593 2件: DRD2,
HTR1A 💬		10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬2件: 6, 51
970Buspirone Hydrochloride1件: Buspirone1件: D07593 2件: DRD2,
HTR1A 💬		10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬1件: 6
971Busulfan1件: Busulfan1件: D00248 --13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326
972Busulfan test dose1件: Busulfan1件: D00248 --1件: 65
973Busulfan, Cyclophosphamide, Antithymocyte Globulin2件: Busulfan,
Cyclophosphamide		3件: D00248 ,
D00287 ,
D07760 		--2件: 19, 20
974Busulfan, Cyclophosphamide, ATG2件: Busulfan,
Cyclophosphamide		3件: D00248 ,
D00287 ,
D07760 		--1件: 19
975Busulfan, Cyclophosphamide, ATG, GCSF2件: Busulfan,
Cyclophosphamide		3件: D00248 ,
D00287 ,
D07760 		--2件: 65, 284
976Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)4件: Antithymocyte immunoglobulin (rabbit),
Busulfan,
Cyclophosphamide,
Fludarabine		4件: D00248 ,
D00287 ,
D07760 ,
D07966 		1件: RRM1 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬1件: 326
977Busulfan, Fludarabine and ATG2件: Busulfan,
Fludarabine		2件: D00248 ,
D07966 		1件: RRM1 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬1件: 65
978Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.4件: Busulfan,
Cyclophosphamide,
Cyclosporine,
Fludarabine		5件: D00184 ,
D00248 ,
D00287 ,
D07760 ,
D07966 		6件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2,
RRM1 💬		39件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Nucleotide metabolism, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬2件: 60, 285
979Busulfan, Fludarabine, ATG, TLI2件: Busulfan,
Fludarabine		2件: D00248 ,
D07966 		1件: RRM1 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬2件: 65, 284
980Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF6件: Busulfan,
Filgrastim,
Fludarabine,
Methotrexate,
Phosphate ion,
Tacrolimus		6件: D00107 ,
D00142 ,
D00248 ,
D03235 ,
D07966 ,
D08556 		9件: CSF3R,
DHFR,
DHFR2,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2,
RRM1 💬		48件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Antifolate resistance, Axon guidance, B cell receptor signaling pathway, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Drug metabolism - other enzymes, Folate biosynthesis, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Nucleotide metabolism, One carbon pool by folate, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 60
981BUSULFANO1件: Busulfan1件: D00248 --1件: 19
982Butanoic acid1件: Butyric Acid---3件: 34, 51, 97
983Butylphthalide1件: Butylphthalide---4件: 2, 6, 18, 22
984Butyrate1件: Butyric Acid---4件: 46, 97, 156, 291
985Butyrate enemas + routine management1件: Butyric Acid---1件: 291
986Butyric Acid1件: Butyric Acid---1件: 222
987BUU 0.4mg/ml----1件: 98
988BV-101----1件: 8
989BVS857----1件: 1
990BX-1----1件: 13
991By demand----2件: 96, 97
992BYDUREON1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬2件: 6, 17
993Bydureon 2 mg powder and solvent for prolonged-release suspension2件: Exenatide,
Manganese citrate		1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 6
994Byetta1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬3件: 6, 78, 193
995Byetta 5 micrograms1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 6
996BYM338----1件: 15
997BYM338 (Bimagrumab)1件: Bimagrumab1件: D10620 2件: ACVR2A,
ACVR2B 💬		4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 15
998BYM338/bimagrumab1件: Bimagrumab1件: D10620 2件: ACVR2A,
ACVR2B 💬		4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬1件: 15
999Béfizal----1件: 302